Amgen (AMGN) Stock Forecast & Price Target

Compare

6,650 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

9 Buy

11 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$323.00

▲(9.29% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $323.00 with a high forecast of $405.00 and a low forecast of $272.00. The average price target represents a 9.29% change from the last price of $295.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"253":"$253","406":"$406","291.25":"$291.3","329.5":"$329.5","367.75":"$367.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$405.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":323,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$323.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$272.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[253,291.25,329.5,367.75,406],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,306.6923076923077,314.88461538461536,323.0769230769231,331.2692307692308,339.46153846153845,347.65384615384613,355.8461538461538,364.03846153846155,372.2307692307692,380.4230769230769,388.61538461538464,396.80769230769226,{"y":405,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,300.38461538461536,302.2692307692308,304.15384615384613,306.03846153846155,307.9230769230769,309.8076923076923,311.6923076923077,313.5769230769231,315.46153846153845,317.34615384615387,319.2307692307692,321.11538461538464,{"y":323,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,296.46153846153845,294.4230769230769,292.38461538461536,290.34615384615387,288.3076923076923,286.2692307692308,284.2307692307692,282.1923076923077,280.15384615384613,278.11538461538464,276.0769230769231,274.03846153846155,{"y":272,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":309.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":254.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$405.00

Average Price Target$323.00

Lowest Price Target$272.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Jay Olson

Oppenheimer

$380

Buy

28.58%

Upside

Reiterated

10/03/25

Oppenheimer Sticks to Its Buy Rating for Amgen (AMGN)

Geoff Meacham

Citi

$315

Hold

6.58%

Upside

Reiterated

10/03/25

Citi Remains a Hold on Amgen (AMGN)

Yaron Werber

TD Cowen

$389

Buy

31.62%

Upside

Reiterated

10/02/25

TD Cowen Remains a Buy on Amgen (AMGN)

David Amsellem

Piper Sandler

$342

Buy

15.72%

Upside

Reiterated

10/02/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

$306→$310

Buy

4.89%

Upside

Upgraded

10/01/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

$335

Buy

13.35%

Upside

Reiterated

09/30/25

Bernstein Reaffirms Their Buy Rating on Amgen (AMGN)We rate LLY, GILD, AMGN Outperform & PFE, BMY, MRK, ABBV, MRNA as Market-Perform.

Tim Anderson

Bank of America Securities

$272

Sell

-7.97%

Downside

Reiterated

09/26/25

Bank of America Securities Sticks to Their Sell Rating for Amgen (AMGN)

Chris Schott

J.P. Morgan

$300

Hold

1.51%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)We are establishing a Dec 2026 price target of $300 (vs prior Dec 2025 PT of $300)

Vamil Divan

Guggenheim

$288

Hold

-2.55%

Downside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges4:04 PM Research | Healthcare Amgen Inc. (AMGN) $283.18 Market Value (M): $152,453 Biotechnology Matt Phipps, Ph.D.

Salim Syed

Mizuho Securities

$280

Hold

-5.26%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Carter Gould

Cantor Fitzgerald

$305

Hold

3.20%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $305.00 price target on Amgen (NASDAQ: AMGN).

Trung Huynh

UBS

$326→$317

Hold

7.26%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Jay Olson

Oppenheimer

$380

Buy

28.58%

Upside

Reiterated

10/03/25

Oppenheimer Sticks to Its Buy Rating for Amgen (AMGN)

Geoff Meacham

Citi

$315

Hold

6.58%

Upside

Reiterated

10/03/25

Citi Remains a Hold on Amgen (AMGN)

Yaron Werber

TD Cowen

$389

Buy

31.62%

Upside

Reiterated

10/02/25

TD Cowen Remains a Buy on Amgen (AMGN)

David Amsellem

Piper Sandler

$342

Buy

15.72%

Upside

Reiterated

10/02/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

$306→$310

Buy

4.89%

Upside

Upgraded

10/01/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

$335

Buy

13.35%

Upside

Reiterated

09/30/25

Bernstein Reaffirms Their Buy Rating on Amgen (AMGN)We rate LLY, GILD, AMGN Outperform & PFE, BMY, MRK, ABBV, MRNA as Market-Perform.

Tim Anderson

Bank of America Securities

$272

Sell

-7.97%

Downside

Reiterated

09/26/25

Bank of America Securities Sticks to Their Sell Rating for Amgen (AMGN)

Chris Schott

J.P. Morgan

$300

Hold

1.51%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)We are establishing a Dec 2026 price target of $300 (vs prior Dec 2025 PT of $300)

Vamil Divan

Guggenheim

$288

Hold

-2.55%

Downside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Salim Syed

Mizuho Securities

$280

Hold

-5.26%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Carter Gould

Cantor Fitzgerald

$305

Hold

3.20%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $305.00 price target on Amgen (NASDAQ: AMGN).

Trung Huynh

UBS

$326→$317

Hold

7.26%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

22/41 ratings generated profit

Average Return

+0.72%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.66% of your transactions generating a profit, with an average return of +0.72% per trade.

3 Months

xxx

Success Rate

26/41 ratings generated profit

Average Return

+4.33%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.41% of your transactions generating a profit, with an average return of +4.33% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

31/41 ratings generated profit

Average Return

+11.46%

reiterated a buy rating 7 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 75.61% of your transactions generating a profit, with an average return of +11.46% per trade.

2 Years

xxx

Success Rate

33/41 ratings generated profit

Average Return

+13.66%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.49% of your transactions generating a profit, with an average return of +13.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 21 Buy Ratings, 19 Hold Ratings, and 2 Sell Ratings. AMGN average Analyst price target in the past 3 months is 323.00.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $5.05 with a range of $4.20 to $5.46. The previous quarter’s EPS was $6.02. AMGN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AMGN has Preformed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.99B with a range of $8.78B to $9.20B. The previous quarter’s sales results were $9.17B. AMGN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AMGN has Preformed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 323.00.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen has 9.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 9 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 323.00. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $405.00 ,the lowest forecast is $272.00. The average price target represents 9.29% Increase from the current price of $295.54.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts